A novel hybrid aspirin-NO-releasing compound inhibits TNFalpha release from LPS-activated human monocytes and macrophages

BACKGROUND: The cytoprotective nature of nitric oxide (NO) led to development of NO-aspirins in the hope of overcoming the gastric side-effects of aspirin. However, the NO moiety gives these hybrids potential for actions further to their aspirin-mediated anti-platelet and anti-inflammatory effects....

Descripción completa

Detalles Bibliográficos
Autores principales: Turnbull, Catriona M, Marcarino, Paolo, Sheldrake, Tara A, Lazzarato, Loretta, Cena, Clara, Fruttero, Roberta, Gasco, Alberto, Fox, Sarah, Megson, Ian L, Rossi, Adriano G
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2525633/
https://www.ncbi.nlm.nih.gov/pubmed/18671842
http://dx.doi.org/10.1186/1476-9255-5-12

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2525633/
https://www.ncbi.nlm.nih.gov/pubmed/18671842
http://dx.doi.org/10.1186/1476-9255-5-12

Ejemplares similares